他泽司他治疗肉瘤的效果和副作用是什么？

Epithelioid sarcoma is a very rare and aggressive soft tissue sarcoma that represents a novel treatment approach for patients with advanced or metastatic epithelioid sarcoma who are not candidates for curative surgery. On January 23, 2020, the US FDA approved tazerestat for the treatment of adult and pediatric patients 16 years and older with metastatic/locally advanced epithelioid sarcoma (ES) who are not suitable for complete resection.

Data on the effectiveness of tazerestat in the treatment of sarcoma!

Overall response rate (ORR) and duration of response (DOR) data from a phase II clinical trial involving 62 patients in the epithelioid sarcoma cohort. Data from this cohort were presented at the American Society of Clinical Oncology (ASCO) annual meeting. The results showed that treatment with tazerestat resulted in clinically meaningful and durable responses and was safe and well-tolerated. Among these 62 patients, 24 were treatment-naive patients and 38 were relapsed and/or refractory patients.

Data with a median follow-up of 14 months (0.4-31) showed that the overall response rate (ORR) was 15%, including a complete response rate (CR) of 1.6% and a partial response rate (PR) of 13%. Of the 9 patients who experienced remission, 6 (67%) had remission lasting 6 months or longer.

What are the side effects of tazetostat?

Currently, tazerestat can treat epithelioid sarcoma and follicular lymphoma. Different symptoms have different side effects. The main side effects of tazerestat in the treatment of sarcoma are pain, fatigue, nausea, decreased appetite, vomiting and constipation; the main side effects of tazerestat in the treatment of patients with follicular lymphoma are fatigue, upper respiratory tract infection, musculoskeletal pain, nausea and abdominal pain. It is recommended that patients pay attention to their own reactions after taking the drug. Generally speaking, the safety of tazerestat is tolerable.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: